Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Infect Dis ; 203(9): 1282-91, 2011 May 01.
Article in English | MEDLINE | ID: mdl-21335561

ABSTRACT

The pathophysiology of dengue virus infection remains poorly understood, although secondary infection is strongly associated with more severe disease. In the present study, we performed a nested, case-control study comparing the responses of pre-illness peripheral blood mononuclear cells between children who would subsequently develop either subclinical or symptomatic secondary infection 6-11 months after the baseline blood samples were obtained and frozen. We analyzed intracellular cytokine production by CD4(+) and CD8(+) cells in response to stimulation with dengue antigen. We found higher frequencies of dengue virus-specific TNFα, IFNγ-, and IL-2-producing T cells among schoolchildren who subsequently developed subclinical infection, compared with those who developed symptomatic secondary dengue virus infection. Although other studies have correlated immune responses during secondary infection with severity of disease, to our knowledge this is the first study to demonstrate a pre-infection dengue-specific immune response that correlates specifically with a subclinical secondary infection.


Subject(s)
Cytokines/biosynthesis , Dengue Virus/immunology , Dengue/immunology , Dengue/pathology , T-Lymphocytes/immunology , Adolescent , Case-Control Studies , Child , Humans
2.
Antiviral Res ; 66(2-3): 99-102, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15911026

ABSTRACT

Preliminary data examining interferon alfacon1 treatment of SARS-CoV (severe acute respiratory syndrome-corona virus)-infected patients suggests this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection (CPE) assay, interferon alfacon1 inhibited the generation of CPE in a dose-dependent manner with an IC50 of 0.001 microg/ml, a clinically achievable level. Furthermore, interferon alfacon1 also demonstrated significant antiviral activity in yield reduction and plaque reduction assays. The in vitro antiviral activity of interferon alfacon1 against SARS-CoV suggests continued evaluation of interferon alfacon1 as a therapeutic treatment for patients infected with SARS-CoV.


Subject(s)
Antiviral Agents/pharmacology , Interferon Type I/pharmacology , Severe acute respiratory syndrome-related coronavirus/drug effects , Cytopathogenic Effect, Viral , Humans , Interferon Type I/pharmacokinetics , Interferon-alpha , Microbial Sensitivity Tests , Models, Biological , Recombinant Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...